Department of Endocrinology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Breast and Thyroid Surgical Department, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China.
Brain Behav. 2021 May;11(5):e02081. doi: 10.1002/brb3.2081. Epub 2021 Mar 10.
SITSH (syndrome of inappropriate secretion of thyrotropin) is a rare clinical state defined as uninhibited serum thyroid stimulating hormone in the presence of elevated thyroid hormone. This state is complicated and mainly caused by the abnormal feedback of hypothalamus-pituitary thyroid axis. The TSH adenoma (TSH-oma) and resistance to thyroid hormones (RTH) are the main etiologies of SITSH. As is well known that the treatment strategies of RTH and TSH-oma are apparently different, thus identifying the difference between RTH and TSH-oma is of great significance for the diagnosis and treatment of SITSH. CASE DESCRIPTION: A 62-year-old man with a state of elevated thyroid hormones and inappropriate elevated serum TSH level was hospitalized in 2016. Results of the pituitary enhanced magnetic resonance imaging and the somatostatin test respectively demonstrated a space-occupying lesion of pituitary and an elevated serum sex hormone binding globulin (SHBG) and inhibited TSH secretion, which indicated the occurrence of TSH-oma. In 2019, a 23-year-old girl with a state of elevated thyroid hormones and inappropriate normal serum TSH was hospitalized. Interestingly, whole exome sequencing detection suggested a pathogenic mutation in thyroid hormone receptor β (THRB) gene, which has been shown to be associated with RTH. CONCLUSIONS: The difference between TSH-oma and RTH ought to be clarified for their accurate diagnose and treatment. The clinical experiences of the two cases reported here suggest that more detail information such as family medical history, serum SHBG level, and THRB gene test is helpful for the diagnose and treatment of TSH-oma and RTH. Additionally, we also summarized the identification points, diagnosis process, and treatment strategies for these two rare diseases.
甲状腺刺激素不适当分泌综合征(SITSH)是一种罕见的临床状态,定义为甲状腺激素升高时血清促甲状腺激素不受抑制。这种状态很复杂,主要是由于下丘脑-垂体-甲状腺轴的异常反馈引起的。促甲状腺激素腺瘤(TSH-oma)和甲状腺激素抵抗(RTH)是 SITSH 的主要病因。众所周知,RTH 和 TSH-oma 的治疗策略明显不同,因此,区分 RTH 和 TSH-oma 对于 SITSH 的诊断和治疗具有重要意义。
一位 62 岁男性,于 2016 年因甲状腺激素升高和不适当升高的血清 TSH 水平住院。垂体增强磁共振成像和生长抑素试验结果分别显示垂体占位性病变和血清性激素结合球蛋白(SHBG)升高和 TSH 分泌抑制,提示发生了 TSH-oma。2019 年,一位 23 岁女性因甲状腺激素升高和不适当正常的血清 TSH 水平住院。有趣的是,全外显子组测序检测提示甲状腺激素受体β(THRB)基因突变,该突变与 RTH 相关。
为了准确诊断和治疗,应明确区分 TSH-oma 和 RTH。这里报告的两个病例的临床经验表明,家族病史、血清 SHBG 水平和 THRB 基因检测等更详细的信息有助于诊断和治疗 TSH-oma 和 RTH。此外,我们还总结了这两种罕见疾病的鉴别要点、诊断流程和治疗策略。